PSI CRO opens in Taiwan, looks to Hong Kong for 2018

By Melissa Fassbender contact

- Last updated on GMT

(Image: lovelyday12)
(Image: lovelyday12)

Related tags: Asia pacific, Ulcerative colitis

The Switzerland-headquartered contract research organization (CRO) has opened offices in Taiwan following a string of investments in the Asia Pacific region.

The new office will be listed as Taiwan PSI Health Development Co. Ltd.

According to the CRO, its expansion​ has been driven by demand in oncology, infections, IBD (ulcerative colitis, Crohn’s Disease), and other therapeutic areas.

Taiwan is an important contributor to global clinical trials​,” said Olga Alfonsova, head of corporate development at PSI CRO.

That’s why PSI has opened an office in Taipei and will continue to grow within the country to access the most prominent investigative sites in the areas of oncology, infections, inflammatory bowel diseases, neurology and other therapeutic areas​,” she told us.

The Switzerland-based company is “perfectly on track​” with its plans to expand into Asia Pacific, said Alfonsova. So far this year the company has established offices in Sydney, Australia; Seoul, South Korea, and Taipei; Taiwan.

Alfonsova explained Hong Kong will be next at the beginning of 2018.

The expansion into Asia Pacific region is well-paced and allows global sponsors access to Asian populations across a variety of therapeutic indications​,” she added.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars